Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
Addex Therapeutics Ltd - American Depositary Shares (ADXN)
Company Research
Source: GlobeNewswire
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023 and first quarter 2024 results primarily due to the sale of part of its business to Neurosterix Pharma Sàrl on April 2, 2024. The provisional result amount to a net gain of CHF 9.8 million for the six-month period ended June 30, 2024 compared to a net loss of CHF 5.1 million for the six-month period ended June 30, 2023. The increase of CHF 14.9 million is primarily due to the gross proceeds of CHF 5.0 million received in cash from the sale of a part of Addex’s business and the fair value of the 20% equity interest in Neurosterix US holdings LLC received as part of the consid
Show less
Read more
Impact Snapshot
Event Time:
ADXN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADXN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADXN alerts
High impacting Addex Therapeutics Ltd - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADXN
News
- Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference [Yahoo! Finance]Yahoo! Finance
- Addex to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Addex Therapeutics Ltd (NASDAQ: ADXN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder [Yahoo! Finance]Yahoo! Finance
- Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research CollaborationGlobeNewswire
ADXN
Sec Filings
- 9/19/24 - Form 6-K
- 8/27/24 - Form 6-K
- 8/14/24 - Form SC
- ADXN's page on the SEC website